OliX Pharmaceuticals Statistics

Total Valuation

OliX Pharmaceuticals has a market cap or net worth of KRW 459.55 billion. The enterprise value is 483.63 billion.

Market Cap	459.55B
Enterprise Value	483.63B

Important Dates

The next estimated earnings date is Wednesday, November 13, 2024.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	n/a

Share Statistics

OliX Pharmaceuticals has 17.08 million shares outstanding. The number of shares has increased by 15.40% in one year.

Shares Outstanding	17.08M
Shares Change (YoY)	+15.40%
Shares Change (QoQ)	+0.93%
Owned by Insiders (%)	21.11%
Owned by Institutions (%)	15.88%
Float	13.48M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	23.78
PB Ratio	17.47
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-24.52
EV / Sales	27.02
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-16.58

Financial Position

The company has a current ratio of 0.91, with a Debt / Equity ratio of 1.81.

Current Ratio	0.91
Quick Ratio	0.86
Debt / Equity	1.81
Debt / EBITDA	n/a
Debt / FCF	-1.64
Interest Coverage	-4.45

Financial Efficiency

Return on equity (ROE) is -57.19% and return on invested capital (ROIC) is -12.83%.

Return on Equity (ROE)	-57.19%
Return on Assets (ROA)	-10.35%
Return on Capital (ROIC)	-12.83%
Revenue Per Employee	248.60M
Profits Per Employee	-273.91M
Employee Count	72
Asset Turnover	0.18
Inventory Turnover	0.30

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +9.37% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+9.37%
50-Day Moving Average	15,877.20
200-Day Moving Average	14,739.15
Relative Strength Index (RSI)	81.44
Average Volume (20 Days)	563,027

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, OliX Pharmaceuticals had revenue of KRW 17.90 billion and -19.72 billion in losses. Loss per share was -1,246.76.

Revenue	17.90B
Gross Profit	17.68B
Operating Income	-16.64B
Pretax Income	-20.67B
Net Income	-19.72B
EBITDA	-14.00B
EBIT	-16.64B
Loss Per Share	-1,246.76

Full Income Statement

Balance Sheet

The company has 24.44 billion in cash and 47.74 billion in debt, giving a net cash position of -23.30 billion or -1,363.85 per share.

Cash & Cash Equivalents	24.44B
Total Debt	47.74B
Net Cash	-23.30B
Net Cash Per Share	-1,363.85
Equity (Book Value)	26.40B
Book Value Per Share	1,539.68
Working Capital	-2.97B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -19.42 billion and capital expenditures -9.75 billion, giving a free cash flow of -29.17 billion.

Operating Cash Flow	-19.42B
Capital Expenditures	-9.75B
Free Cash Flow	-29.17B
FCF Per Share	-1,707.70

Full Cash Flow Statement

Margins

Gross margin is 98.76%, with operating and profit margins of -92.96% and -110.18%.

Gross Margin	98.76%
Operating Margin	-92.96%
Pretax Margin	-115.49%
Profit Margin	-110.18%
EBITDA Margin	-78.24%
EBIT Margin	-92.96%
FCF Margin	-162.99%

Dividends & Yields

OliX Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.40%
Shareholder Yield	-15.40%
Earnings Yield	-4.63%
FCF Yield	-6.35%

Stock Splits

The last stock split was on December 3, 2020. It was a forward split with a ratio of 2.

Last Split Date	Dec 3, 2020
Split Type	Forward
Split Ratio	2

Scores

OliX Pharmaceuticals has an Altman Z-Score of -0.42. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.42
Piotroski F-Score	n/a